8/5, 12:34 PM (Source: TeleTrader)
more TeleTrader news


Chart for: Moderna

Moderna's Q2 revenue surges to $4.4 billion

Moderna Inc. unveiled on Thursday that its revenue for the second quarter of its fiscal year climbed to $4.4 billion, eclipsing the $67 million it had for the same period last year.

At the same time, the company's net income stood at $2.8 billion surging from last year's net loss of $117 million. Lastly, Moderna reported a significant climb in its diluted earnings (loss) per share, going from a loss per share of $0.31 in 2020 to earnings per share of $6.46 in 2021.

Stéphane Bancel, Chief Executive Officer of Moderna, commented on the results: "We now have mRNA candidates in clinical trials across five therapeutic areas including infectious diseases, cardiovascular, oncology, rare disease, and autoimmune disorders. We are pleased that our COVID-19 vaccine is showing durable efficacy of 93% through six months, but recognize that the Delta variant is a significant new threat so we must remain vigilant."

Moderna shares were up 0.22% following the release report.

Breaking the News / OL